Trial Profile

A Phase 1b/2a Study of Amilo 5MER for Biomarkers (SAA in Serum) for Inflammatory Bowel Disease (IBD)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 28 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amilo-5MER (Primary)
Indications Inflammatory bowel diseases
Focus Biomarker; Pharmacodynamics
Sponsors EoCene

Most Recent Events

09 Sep 2026 According to an Eocene media release, the Galmed Pharmaceuticals is now called Eocene.
13 Aug 2020 New trial record
06 Aug 2020 According to a Galmed Pharmaceuticals media release, initiation of this phase 1b/2a study for biomarkers (SAA in serum) for IBD is planned in H2 21.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com